Biomedical subjects

H M Guddat

Publications and source records attributed to H M Guddat.

17 recordsLinked to original sources

PubMed1987

[Tuberculous prostatitis within the scope of urogenital tuberculosis--pathogenetic and diagnostic aspects].

208 males with tuberculosis of the urogenital system showed a participation of prostate in 110 cases (53%), however, in 52 transrectal punch biopsies of the prostate only 25 times a tuberculosis could histologically be proved. An isolated tuberculosis of the prostate was found only in 6 males (5.4%), in most cases accidentally in biopsies of the prostate, after adenomectomy of the prostate or TURP. The way of the infection of the tuberculosis of the male genitals and the question of the primary focus on the genitals remained unclarified.

Biopsy↗

PubMed1987

[Conservative therapy of prostate cancer using Turisteron].

Turisteron is an orally highly effective depot estrogen (ethinylestradiol sulfonate) with relatively slight side effects. The treatment with Turisteron is very effective and is well tolerated by the patient. A strong antiandrogenic effect could be produced which had as its sequel a significant increase of the survival rates of patients with carcinoma of the prostate gland. The weekly dosage of 2 mg Turisteron led to a decrease of the biologically active, free testosterone to less than 2% compared with the initial value. The decrease of the total testosterone to castration values and the decrease of the free testosterone still significantly below values of castration are evidences for the strong antiandrogenic effect in exclusive estrogen treatment with Turisteron. From this conclusions relevant to practice were derived and finally therapy recommendation for the conservative treatment of the carcinoma of the prostate gland were given.

Aged↗

PubMed1987

[Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)].

45 patients with prostatic cancer were treated conservatively with Turisteron at a dosage of 2 mg per week. After 2 months the serum levels of total testosterone were reduced to castration values and thereafter furthermore to 6% of the pretreatment values. The free testosterone (FT) serum level did show a decrease to 2%, while the binding capacity of the sexual hormone binding globulin (SHBG) was increased from 4,1% to 97,9%. The serum levels of the two gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were decreased only to nearly 20% of the pretreatment value. The investigations confirm the definite "antiandrogenic" effect of Turisteron, which is 10-times higher than the antigonadotropic effect.

Ethinyl Estradiol↗

PubMed1987

[Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer].

Turisteron proves to be a highly effective, poor in side effects, orally applicable estrogen preparation for the hormone therapy of the carcinoma of the prostate under the conditions of the routine practice. The cumulative 5-year survival rates of 197 patients observed of all categories of tumours (T1-4NxM0-1) were 66 +/- 10% and were depending upon the local growth of the tumour and upon the degree of metastasation between 81 +/- 18% and 47 +/- 42%. A discontinuation of the therapy due to strong side effects was necessary only in 4 cases (2.07%).

Adult↗

PubMed1987

[Clinical study of ethinyl estradiol sulfonate in conservative therapy of prostate cancer].

Ethinylestradiol sulfonate is an orally applicable, potent depot estrogen with steroid structure. With a dosage of 2 mg per week it shows a distinct antigonadotropic and antiandrogenic effect. Its suitability for the hormone therapy of the carcinoma of the prostate is clinically and cytologically confirmed. It seldom has undesirable side effects. The oral application necessary only once a week guarantees a continuous supply of active substances with a good compliance by the patients.

Adenocarcinoma↗

PubMed1984

[Results of ligature of the upper testicular vein in idiopathic varicocele and subfertility].

The results of a total of 102 varicocele operations, 83 of which were performed because of subfertility and a desire to have children, are presented. In 3% of the cases a recidive operation was necessary because of persistent varicocele. 55 patients with limited fertility were subsequently examined for volume, density and form of sperm, total motility and propulsive motility. Whereas the volume of sperm and the total motility remained unchanged, the density and form of sperm and the propulsive motility had improved significantly 9 months after the operation. Among the men followed up the conception rate was 20%.

Adult↗

PubMed1983

[High-voltage therapy of prostate cancer].

High-voltage therapy is becoming increasingly important as a form of individual differential therapy of carcinoma of the prostate. Around 40% of all patients with a diagnosis of carcinoma of the prostate can be treated with high-voltage therapy. The precondition is the absence of bone and soft-tissue metastases and of juxtaregional lymph-node metastases. Individual carcinoma therapy is based on pre-therapeutic tumor classification according to the TNM system. The 5-year survival rates are presented from a retrospective study carried out using primary radiation monotherapy and a combined hormone and radiation therapy; these figures were calculated by the life-table method. The study revealed no significant differences between the two forms of therapy as regards 5-year survival rates. The 5-year survival rates of all patients of the classifications T0-T3Nx-N2M0 irradiated (n: 198) (72% +/- 11% for hormone plus radiation therapy and 74% +/- 11% for radiation monotherapy) did not differ greatly from those of a normal male population of the same age (77%). High-voltage therapy of carcinoma of the prostate can thus be classified as a curative method of treatment.

Aged↗

PubMed1979

[Diagnostics and therapy of the carcinoma of the prostate (author's transl)].

By well organized preventive examinations early tumour stages can be recognized. The diagnosis of prostatic cancer has to be secured by biopsy. The primary reliability of aspiration biopsies (cytology) was 94% compared with punch biopsies (histology) amounting to 73%. Indications and results of aspiration biopsies, radiological and nuclear medical techniques in diagnosing prostatic cancer are described. The combined anti-androgenic hormonal therapy (infusions of cytonal, subcapsular orchiectomy, permanent administration of oestrogen) is considered to be the unchanged basis of treatment. Comparative cytologic investigations in therapy indicate that high-voltage treatment connected with hormonal therapy seems to be superior to exclusive hormonal treatment. Observations after additional therapy by a radionuclid (89-Strontium) for affecting metastases are encouraging. Indications of a therapy by cytostatica in progressive prostatic cancer are explained.

Antineoplastic Agents↗

PubMed1979

[Initial experience with ethinyl estradiol sulfonate (J 96) in the therapy of prostate carcinoma].

Ethinylestradiol sulphate (J 96) is a depot estrogen which in a dosage of 2 mg per week has clearly antigonadotropic effects and evokes a suppression of the free testosterone in bilaterally orchiectomized patients with carcinoma of the prostate. The good compatibility in oral application and the possibility for the controlled intake recommend its use for the long-term therapy of the carcinoma of the prostate.

Carcinoma↗

PubMed1979

[Kidney cyst puncture for diagnosis and therapy].

It is reported on 38 punctures of avascular space occupying lesions of the kidney. The method is little stressing and poor of risk. It is recommended above all for older patients for the exclusion of an avascular tumour or a tumour within a cyst. The demonstration of the cyst in the double contrast may be performed following the angiography. The simultaneous therapeutic effect of the obliteration of a benign cyst be instillation of Propyliodon and Vistarin is desirable. A positive effect (complete obliteration including essential shrinking) was observed in 91%. Roentgenograms without contrast medium are not sufficient for course control. When the results of the demonstration of the hollow space, the cytology and the arteriography are unclear, operation is recommended.

Adult↗

PubMed1977

[Diagnostic and treatment of prostatic cancer (author's transl)].

The diagnosis of prostatic cancer must be proved by biopsy. Transrectal fine needle biopsy and punch biopsy are also useful methods for the outpatient clinic. Besides X-ray examination scanning angiography and lymphography may be used to identify metastases. Combined antiandrogenic therapy is still the treatment of choice and is based on endocrinologic analysis of testosterone, LH levels and testosterone-binding beta-globulin. Radionuclids (32P, 89Sr) should be used for treating metastases of the bone. Chemotherapeutic substances showed unsatisfactory results. Radical prostatectomy can only be performed in 5 to 10% of all patients with prostatic cancer to metastases in T1 and T2 cases. Since 1965 the radiation therapy (linear accelerator or (60Co-source) gives more hope. We treat patients free from metastases with a 60Co-source (right and left lateral 120-degree arc rotational therapy with 5000 rads over 5 weeks) combined with hormonal therapy. The therapeutic effect is checked by fine needle aspiration biopsy.

Antineoplastic Agents↗

PubMed1977

[Anuria--a geriatric emergency situation].

The missing output of urine is an emergency case which is problematic with regard to old patients. This situation is caused by disturbances of renal function (anuria) or by acute ureteric obstruction or by complete ischuria. The possibilities of differential diagnosis and etiology have been illustrated. Anuria and acute ureteric obstruction need a treatment by urological or nephrological specialists, but each doctor must be able in cases of complete ischuria to empty the bladder by catheterization or by suprapubic puncture.

Anuria↗

PubMed1975